Zobrazeno 1 - 10
of 231
pro vyhledávání: '"Kenichi, Suda"'
Autor:
Shuta Ohara, Kenichi Suda, Akira Hamada, Masato Chiba, Masaoki Ito, Masaki Shimoji, Toshiki Takemoto, Junichi Soh, Yasuhiro Tsutani
Publikováno v:
Thoracic Cancer, Vol 15, Iss 31, Pp 2229-2234 (2024)
Abstract Background Superior outcomes have been obtained for neoadjuvant treatment with immune checkpoint inhibitors (ICI) plus chemotherapy over neoadjuvant chemotherapy alone, especially in patients with high programmed cell death ligand 1 (PD‐L1
Externí odkaz:
https://doaj.org/article/01fa212b64f949ff8f69a1fbe25e8ccd
Autor:
Rie Shimizu, Kenichi Suda, Toshiki Takemoto, Shota Fukuda, Masato Chiba, Masaki Shimoji, Junichi Soh, Tetsuya Mitsudomi, Yasuhiro Tsutani
Publikováno v:
Surgical Case Reports, Vol 10, Iss 1, Pp 1-5 (2024)
Abstract Background The use of soft coagulation is becoming common in thoracic surgery. Soft coagulation provides rapid hemostasis from small vessels during surgery by dehydrating tissue and denaturing proteins, without burning the tissue. Case prese
Externí odkaz:
https://doaj.org/article/fbb5057d0a6b457fa3cc9b7f19840f04
Autor:
Akira Hamada, MD, PhD, Kazuhiro Kitajima, MD, PhD, Kenichi Suda, MD, PhD, Takamasa Koga, MD, PhD, Junichi Soh, MD, PhD, Hayato Kaida, MD, PhD, Kimiteru Ito, MD, PhD, Tetsuro Sekine, MD, PhD, Kyoshiro Takegahara, MD, PhD, Hiromitsu Daisaki, PhD, Masaki Hashimoto, MD, PhD, Yukihiro Yoshida, MD, PhD, Takanobu Kabasawa, MD, PhD, Takashi Yamasaki, MD, Seiichi Hirota, MD, PhD, Jitsuo Usuda, MD, PhD, Kazunari Ishii, MD, PhD, Tetsuya Mitsudomi, MD, PhD
Publikováno v:
JTCVS Open, Vol 14, Iss , Pp 502-522 (2023)
Objectives: Despite the prognostic impacts of preoperative fluorine-18 fluorodeoxyglucose-positron emission tomography/computed tomography examination, fluorine-18 fluorodeoxyglucose-positron emission tomography/computed tomography–based prognosis
Externí odkaz:
https://doaj.org/article/e19c0aed51314bcc89b498ce4c184a36
Autor:
Shota Fukuda, Kenichi Suda, Akira Hamada, Hana Oiki, Shuta Ohara, Masaoki Ito, Junichi Soh, Tetsuya Mitsudomi, Yasuhiro Tsutani
Publikováno v:
Biomedicines, Vol 12, Iss 7, p 1412 (2024)
The emergence of acquired resistance to EGFR-tyrosine kinase inhibitors (TKIs) is almost inevitable even after a remarkable clinical response. Secondary mutations such as T790M and C797S are responsible for the resistance to 1st/2nd-generation (1/2G)
Externí odkaz:
https://doaj.org/article/13cb6c41316240a794f6123d8ca258da
Autor:
Takamasa Koga, MD, PhD, Junichi Soh, MD, PhD, Akira Hamada, MD, PhD, Yuki Miyano, MS, Toshio Fujino, MD, PhD, Keiko Obata, Shuta Ohara, MD, PhD, Masaya Nishino, MD, PhD, Masato Chiba, MD, PhD, Masaki Shimoji, MD, PhD, Toshiki Takemoto, MD, PhD, Kenichi Suda, MD, PhD, Kazuko Sakai, MD, PhD, Hidenori Sato, PhD, Tetsuya Mitsudomi, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 9, Pp 100554- (2023)
Introduction: Lung tumor organoids (LTOs) have attracted attention as in vitro preclinical models; however, their clinical and experimental applications have not been fully established. Methods: We attempted to establish LTOs from resected specimens
Externí odkaz:
https://doaj.org/article/e9026793576d4c6aace4c65a0c8269ab
Autor:
Toshio Fujino, Kenichi Suda, Takamasa Koga, Akira Hamada, Shuta Ohara, Masato Chiba, Masaki Shimoji, Toshiki Takemoto, Junichi Soh, Tetsuya Mitsudomi
Publikováno v:
Journal of Hematology & Oncology, Vol 15, Iss 1, Pp 1-14 (2022)
Abstract Background Capmatinib and tepotinib are guideline-recommended front-line treatments for non-small-cell lung cancer (NSCLC) patients with MET exon 14 skipping mutations (METex14). However, the emergence of acquired resistance to capmatinib/te
Externí odkaz:
https://doaj.org/article/91f7932bd36f4d28ab9a6bce380f3ecc
Autor:
Kai Guo, Zhiqiang Ma, Yujiao Zhang, Lu Han, Changjian Shao, Yingtong Feng, Fei Gao, Shouyin Di, Zhipei Zhang, Jiao Zhang, Fabrizio Tabbò, Simon Ekman, Kenichi Suda, Federico Cappuzzo, Jing Han, Xiaofei Li, Xiaolong Yan
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 41, Iss 1, Pp 1-19 (2022)
Abstract Background Histone deacetylases (HDACs) play crucial roles in cancers, but the role and mechanism of HDAC7 in NSCLC have not been fully understood. Methods A total of 319 patients with non-small cell lung cancer (NSCLC) who underwent surgery
Externí odkaz:
https://doaj.org/article/abc69dd4f2614b9a80ba91fd95d83a97
Publikováno v:
Biomolecules, Vol 13, Iss 9, p 1377 (2023)
Several clinical trials have been revolutionizing the perioperative treatment of early-stage non-small cell lung cancer (NSCLC). Many of these clinical trials involve cancer immunotherapies with antibody drugs that block the inhibitory immune checkpo
Externí odkaz:
https://doaj.org/article/0444c87989cc455ea42db0fd78dfab72
Autor:
Masaya Nishino, Kenichi Suda, Takamasa Koga, Shuta Ohara, Toshio Fujino, Junichi Soh, Vijaya Tirunagaru, Avanish Vellanki, Robert C. Doebele, Tetsuya Mitsudomi
Publikováno v:
Thoracic Cancer, Vol 12, Iss 10, Pp 1511-1516 (2021)
Abstract Background Approximately 10% of non‐small cell lung cancers (NSCLCs) that harbor epidermal growth factor receptor (EGFR) gene mutations have in‐frame insertions in exon 20 of the EGFR gene. These tumors do not usually respond to currentl
Externí odkaz:
https://doaj.org/article/113f3c44e4bf4bd88a1b39cc70faedeb
Autor:
Akira Hamada, MD, Kenichi Suda, MD, PhD, Toshio Fujino, MD, PhD, Masaya Nishino, MD, PhD, Shuta Ohara, MD, PhD, Takamasa Koga, MD, PhD, Takanobu Kabasawa, MD, PhD, Masato Chiba, MD, PhD, Masaki Shimoji, MD, PhD, Makoto Endoh, MD, PhD, Toshiki Takemoto, MD, PhD, Junichi Soh, MD, PhD, Naoki Yanagawa, MD, PhD, Satoshi Shiono, MD, PhD, Tetsuya Mitsudomi, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 5, Pp 100321- (2022)
Introduction: Recent studies have suggested that including presence or absence of ground-glass opacity (GGO) may improve the tumor descriptor (T descriptor) classification in clinical stage I NSCLC. In this study, we analyzed prognostic implications
Externí odkaz:
https://doaj.org/article/e3038b81b06d4260b05a610326300a03